Patient Assistance Programs Increase Adherence to Oral Oncology Drugs

Jan 12, 2016
Patient Assistance Programs provide needed financial assistance that can help lower-income populations achieve greater medication adherence.
Tags
  • Cancer

Glow Cap Article 

Patient Assistance Programs (PAPs) provide eligible patients with financial assistance for medications that would otherwise be cost-prohibitive. Without these critical programs, the cost impact of specialty medication may lead some patients to forego treatment.

Our research found that participation in PAPs may increase medication adherence for patients taking oral oncology medications.

The Study

Accredo began proactively offering PAPs to patients with cancer in 2014.  PAPs may be funded by manufacturers or offered through foundations or other organizations, cost nothing to payers, and do not affect the drug price charged to patients who do not qualify for the PAP. These programs can provide a critical safety net for patients in need.

We studied patients who had been taking oral oncology medications since the first of quarter 2014. The study compared medication adherence rates of those who enrolled in a PAP in 2015 to adherence rates of patients that did not enroll in a PAP. The patients were matched using demographic information and zip code level census data to determine average household income of the study group and the control group.

The Results

Patients enrolled in a PAP experienced, on average, an 8% increase in medication adherence – a jump in average adherence from 83% to 92% from 2014 to 2015. Adherence for those not enrolled in a PAP decreased on average 2%, from 90% to 88% from 2014 to 2015.

When we analyzed census data, we found that the average median earnings for those utilizing a PAP was $29,381.22, about 19% lower than the $36,222.39 average median income for patients not enrolled in a PAP.

While there was a greater increase in adherence for patients in a PAP, the original adherence of those not involved in a PAP was higher. This suggests that PAPs provide needed financial assistance that can help this lower-income population achieve the same adherence rates as patients not enrolled in PAPs.

The Accredo Difference

During 2015, the Accredo Copay Assistance team helped secure $364 million in financial assistance for patients, which includes an average of $13,000 in financial assistance per eligible oncology patient.

PAPs typically are funded by manufacturers or foundations, cost nothing to payers, and do not affect the drug price charged to patients who do not qualify for the PAP.

Copay assistance helps patients afford critical specialty medications and through increased treatment adherence, helps them achieve healthier outcomes.

Author Bio

Lab Staff
comments powered by Disqus